2019： ☆The iron-based project team was spin-off from LifeTech and established as Biotyx Medical (Shenzhen) Co., Ltd.

2020： ☆Introduced multiple strategic investors including IDG Capital and Cornerstone Investments, and obtained RMB 160 million in Series A financing

2021： ☆IBS Coronary Scaffold phase II begins enrollment ☆Key projects of Guangdong Province: R&D and industrialization of Iron-based Bioresorbable Scaffold.

2022： ☆IBS coronary scaffold completed Phase II clinical trial enrollment. ☆IBS Angel for pediatrics pulmonary vascular scaffold completed the CE registration submission.

2023： ☆IBS coronary scaffold completed Phase III clinical trial enrollment ☆IBS Angel obtained CE certification ☆IBS coronary scaffold completed CE registration submission ☆Shenzhen Science and Technology Major Project: Application and Research of Absorbable Children's Vascular Stent

2024： ☆IRONMAN-II one-year clinical data was released at the EuroPCR, and the IBS Bioresorbable scaffold was selected as the "best highlight" of coronary devices at the EuroPCR conference

2025： ☆IBS is expected to obtain CE certification in the first quarter